Feature Channels: Pharmaceuticals

Filters close
Released: 10-Dec-2020 8:45 AM EST
AI platform developed by NUS researchers finds best combination of available therapies against COVID-19
National University of Singapore (NUS)

Researchers from the National University of Singapore have utilised a ground-breaking AI platform to find an optimal combination of available therapies against COVID-19. The research team identified the drug combination from over 530,000 possibilities within two weeks, cutting down the number of tests typically needed by hundreds of thousands.

Released: 9-Dec-2020 5:05 PM EST
Instrumentation Laboratory Receives US FDA Marketing Authorization for the First Apixaban Diagnostic Test
2020 AACC Annual Scientific Meeting Press Program

Instrumentation Laboratory Receives US FDA Marketing Authorization for the First Apixaban Diagnostic Test

Released: 9-Dec-2020 8:45 AM EST
Most Favored Nation Drug Pricing Rule Will Harm Patient Access and Jeopardize Practice Stability, Rheumatology Leaders Warn
American College of Rheumatology (ACR)

The American College of Rheumatology (ACR) today warned that the Centers for Medicare and Medicaid Services (CMS) interim final rule establishing a “most favored nation” (MFN) payment model for Medicare Part B drugs will dramatically disrupt patient access to critical therapies needed to manage rheumatic diseases and conditions.

Released: 8-Dec-2020 3:10 PM EST
UC Davis Health joins Novavax in testing a new COVID-19 vaccine
UC Davis Health (Defunct)

UC Davis Health will launch a COVID-19 clinical trial with Novavax to test a new coronavirus vaccine. This vaccine has an important advantage: liquid state storage that allows for distribution using standard vaccine channels, unlike the Pfizer and Moderna vaccines that must be stored at subzero temperature.

Released: 8-Dec-2020 10:55 AM EST
CU Cancer Center doctor untangles issues around medical cannabis
University of Colorado Cancer Center

Camille Stewart's article about medical cannabis explains issues around the drug’s legality, makes recommendations for its use before and after surgery and pushes for research on its effects on postoperative patients.

Released: 7-Dec-2020 4:50 PM EST
Novel Therapy is Safe for Non-Hodgkin Lymphoma Patients, Roswell Park-Led Study Finds
Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center’s Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Dr. Hernandez-Ilizaliturri will present the team’s findings today at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held virtually.

Released: 7-Dec-2020 3:30 PM EST
Drug for rare disorder shows promise for treating herpes viruses
University of Illinois Chicago

A drug currently prescribed to treat a rare enzyme deficiency can help cells clear the herpes simplex 1 and herpes simplex 2 viruses, according to a new study published in the journal Science Advances.The new data shows that the antiviral activity of the drug — called phenylbutyrate, or PBA — was even better when used along with acyclovir, a common HSV-1 treatment.

Released: 7-Dec-2020 11:55 AM EST
Yale Cancer Center Study Shows Caplacizumab Not Cost Effective for Rare Blood Disorder
Yale Cancer Center/Smilow Cancer Hospital

In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.

Released: 7-Dec-2020 10:35 AM EST
Novel antibody-drug conjugate shows promising early results in rare blood cancer
University of Texas MD Anderson Cancer Center

A phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center found IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm.

7-Dec-2020 8:45 AM EST
Examining Clostridium Difficile Infection in Blood and Marrow Transplant and Leukemic Patients
Rutgers Cancer Institute of New Jersey

Members of the Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey examined the utilization of a low dose of oral vancomycin, a drug used at higher doses to treat established Clostridium difficile infection (CDI), as a way to prevent CDI in blood and bone marrow transplant (BMT) patients.

Released: 7-Dec-2020 9:00 AM EST
Combination of chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic leukemia
University of Texas MD Anderson Cancer Center

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

Released: 7-Dec-2020 8:20 AM EST
New Biomarker Identifies Patients with Aggressive Lymphoma Who Don’t Respond to Precision Therapy
Perelman School of Medicine at the University of Pennsylvania

A new biomarker discovered by a team that includes researchers from Penn Medicine identifies patients with an aggressive form of lymphoma unlikely to respond to the targeted treatment ibrutinib.

4-Dec-2020 4:40 PM EST
EMBARGOED STUDY: Potential Cancer Therapy May Boost Immune Response
Cedars-Sinai

A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators.

3-Dec-2020 2:30 PM EST
Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers
Dana-Farber Cancer Institute

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

2-Dec-2020 7:35 AM EST
Off-the-Shelf Immune Drug Shows Promise in Aggressive Multiple Myeloma
Perelman School of Medicine at the University of Pennsylvania

A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma.

Released: 4-Dec-2020 2:50 PM EST
New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies
Cedars-Sinai

Cedars-Sinai has launched a center to manufacture the next generation of stem cell and gene therapies that will enable biomedical researchers, government medical programs, commercial entities and others to develop new biologic drugs and propel novel disease discoveries.

Released: 4-Dec-2020 2:30 PM EST
Multiomics, Gentational Cd Exposure, Estrogen Receptor Transactivation, and More Featured in December 2020 Toxicological Sciences
Society of Toxicology

The December 2020 issue of the Society of Toxicology’s official journal, Toxicological Sciences, delivers cutting-edge toxicological research in endocrine toxicology, environmental toxicology, organ-specific toxicology, and more.

Released: 4-Dec-2020 12:00 PM EST
FLCCC Alliance Calls on National HealthAuthorities to Immediately Review Medical Evidence Showing the Efficacy of Ivermectin for the Prevention of COVID-19 and as an Early Outpatient Treatment
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

“Following the swi. review— and subsequent guidance— by the NIH and theCDC of Ivermectin, we expect that Ivermectin’s widespread, immediate use willallow for a rapid and safe re-opening of businesses and schools across the nation—and quickly reduce the strain on overwhelmed ICUs.” —FLCCC Alliance

Released: 4-Dec-2020 8:45 AM EST
Proteolytic Enzymes for Covid-19 Studied in 3D for the First Time in Thailand by Chula Biochemists
Chulalongkorn University

A team of biochemists from Chulalongkorn University became the first researchers in Thailand to study proteolytic enzymes for the Covid–19 virus at a molecular level in 3D, possibly leading to the development of Covid–19 treatments.

   
Released: 3-Dec-2020 1:05 PM EST
Huntsman Cancer Institute Researchers Identify Promising Drug Combination for Melanoma
Huntsman Cancer Institute at the University of Utah

Researchers at Huntsman Cancer Institute at the University of Utah have identified a potential drug combination to treat uveal melanoma, a type of eye cancer. Lead author Amanda Truong, trainee in the McMahon Lab at HCI and student at the U of U, explains uveal melanoma patients frequently have changes in genes called GNAQ and GNA11.

Released: 1-Dec-2020 1:55 PM EST
Supercomputers Help Model Potential SARS-CoV2 Protease Inhibitors for COVID-19
University of California San Diego

A team of researchers recently created a pharmacophore model and conducted data mining of the database of drugs approved by the U.S. Federal Drug Administration (FDA) to find potential inhibitors of papain-like protease of SARS-CoV2, one of the main viral proteins responsible for COVID-19.

   
Released: 1-Dec-2020 1:55 PM EST
Mechanism of action of chloroquine/ hydroxychloroquine for COVID-19 infection
Bentham Science Publishers

The recent serious outbreak of Covid19 has affected (November 13, 2020) 53,796,098 people worldwide, resulting in 37,555,669 recovered, 1,310,250 deaths (Figure 1), and a large number of open cases.

Released: 1-Dec-2020 1:30 PM EST
Statins can save lives, are they being used?
Mayo Clinic

People who have coronary artery disease, stroke or peripheral artery disease often are prescribed a statin, a cholesterol-lowering drug that reduces the risk of heart attack or stroke.In a recent publication in JAMA Network Open, Mayo Clinic researchers identify trends in statin use across the U.S. among people with these diseases, as well as among those who already had a stroke or transient ischemic attack (TIA). Their data indicate that only about 60% of patients are getting the recommended therapy.

Released: 1-Dec-2020 1:10 PM EST
UCLA, UCSF gain FDA approval for prostate cancer imaging technique
University of California, Los Angeles (UCLA), Health Sciences

The University of California’s two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new imaging technique for prostate cancer that locates cancer lesions in the pelvic area and other parts of the body to which the tumors have migrated.

1-Dec-2020 9:45 AM EST
Cannabidiol (CBD) in cannabis does not impair driving, landmark study shows
University of Sydney

A landmark study on how cannabis affects driving ability has shown that cannabidiol (CBD), a cannabis component now widely used for medical purposes, does not impair driving, while moderate amounts of the main intoxicating component tetrahydrocannabinol (THC) produce mild driving impairment lasting up to four hours.

30-Nov-2020 2:30 PM EST
CEL-SCI’s Leaps Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies
Cel-Sci Corp

CEL-SCI Corporation announced today its LEAPS COV-19 peptides, delivered as a therapeutic treatment following SARS-CoV-2 virus challenge, achieved a 40% survival rate in transgenic mouse models as compared to 0% survival in the two control groups in studies conducted at the University of Georgia Center for Vaccines and Immunology.

Released: 1-Dec-2020 8:45 AM EST
Environmental exposures affect therapeutic drugs
University of Vienna

High-resolution mass spectrometry promotes new methods for analysis. Humans are exposed to various environmental or dietary molecules that can attenuate or even increase the effect of therapeutic drugs. Studies on the industrial chemical bisphenol A and the phytoestrogen genistein, for example, have shown drug-exposome interactions.

Released: 30-Nov-2020 11:20 AM EST
$11M NIH Grant Will Fund Biomedical Research at University of Delaware
University of Delaware

the National Institutes of Health has renewed a Center of Biomedical Research Excellence (COBRE) grant at the University of Delaware. The COBRE research team is focused on discovery of new molecules that can be used to study and treat diseases such as breast cancer, renal cancer, Crohn’s disease, tuberculosis and Legionnaires disease.

Released: 30-Nov-2020 9:45 AM EST
Rutgers Leading Coronavirus Therapeutic Clinical Trial
Rutgers University-New Brunswick

Rutgers is leading a clinical trial assessing the efficacy of a three-drug combination in treating people infected with SARS-CoV-2 and asymptomatic or mildly symptomatic.

Released: 25-Nov-2020 11:05 AM EST
COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
University of Alabama at Birmingham

Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

Released: 25-Nov-2020 11:00 AM EST
New mechanism of pain control revealed
Kyushu University

Researchers in Japan have revealed a previously unknown mechanism for pain control involving a newly identified group of cells in the spinal cord, offering a potential target for enhancing the therapeutic effect of drugs for chronic pain.

Released: 25-Nov-2020 7:35 AM EST
Warwick scientists design model to predict cellular drug targets against Covid-19
University of Warwick

The covid-19 virus, like all viruses relies on their host for reproduction

   
Released: 24-Nov-2020 3:40 PM EST
New therapy for flu may help in fight against COVID-19
Purdue University

A new therapy for influenza virus infections that may also prove effective against many other pathogenic virus infections, including HIV and COVID-19, has been developed by Purdue University scientists.

   
Released: 24-Nov-2020 8:30 AM EST
Diabetic drug could slow the progression of Parkinson’s disease
University of Warwick

A hallmark of Parkinson's disease is the degeneration of a group of neurons in the brain that release the neurotransmitter dopamine (dopaminergic neurons)

Released: 24-Nov-2020 7:25 AM EST
World’s first: Drug guides stem cells to desired location, improving their ability to heal
Sanford Burnham Prebys

Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy—a scientific first and major advance for the field of regenerative medicine. The discovery, published in the Proceedings of the National Academy of Sciences (PNAS), could improve current stem cell therapies designed to treat such neurological disorders as spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders; and expand their use to new conditions, such as heart disease or arthritis.

   
Released: 23-Nov-2020 5:00 PM EST
CU Cancer Center Leukemia Researcher Receives NCI Outstanding Investigator Award
University of Colorado Cancer Center

Craig Jordan, PhD, has spent more than 20 years developing better treatments for acute myeloid leukemia (AML), a rapidly progressing cancer of the blood and bone marrow that can spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system.

Released: 23-Nov-2020 3:35 PM EST
NYU, Columbia, and Takeda Form Research Alliance for Gastrointestinal and Liver Disorders
New York University

New York University, Columbia University, and Takeda Pharmaceutical Company Limited (“Takeda”) have formed a collaborative research alliance to begin and advance gastroenterology research programs, with the goal of developing new therapies for patients with gastrointestinal and liver disorders.

Released: 23-Nov-2020 11:50 AM EST
Nurse practitioners play key role in opioid addiction treatment in very rural areas
Washington State University

Giving nurse practitioners the authority to prescribe buprenorphine has brought that gold standard treatment for opioid addiction to people who might not have had access to it before, according to a new study led by Tracy Klein, PhD, associate professor at the Washington State University College of Nursing in Vancouver.

Released: 23-Nov-2020 7:55 AM EST
CODA Appendicitis Trial Shows the Risks and Benefits of Treating Appendicitis with Antibiotics Instead of Surgery
RUSH

Antibiotics may be a good treatment choice for some appendicitis patients, according to early results from the Comparing Outcomes of antibiotic Drugs and Appendectomy (CODA) trial reported in the New England Journal of Medicine.

Released: 20-Nov-2020 2:20 PM EST
New treatments for hot flashes target neurons
University of Washington School of Medicine

Specifically, Dr. Susan Reed talked about research into drugs that act at the kisspeptin/neurokinin B/ dynorphin (KNDy) neuron complex in the hypothalamus which controls reproduction and hormonal control. During menopause, estrogen levels decrease, which causes these neurons to be hyperstimulated, thereby causing hot flashes.

Released: 20-Nov-2020 10:40 AM EST
Study: TB Vaccine Linked to Lower Risk of Contracting COVID-19
Cedars-Sinai

A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai. The findings raise the possibility that a vaccine already approved by the U.S. Food and Drug Administration may help prevent coronavirus infections or reduce severity of the disease.

Released: 19-Nov-2020 4:05 PM EST
Collaborative AI effort unraveling SARS-CoV-2 mysteries wins prestigious Gordon Bell Special Prize
Argonne National Laboratory

Using a combination of AI and supercomputing resources, Argonne researchers are examining the dynamics of the SARS-CoV-2 spike protein to determine how it fuses with the human host cell, advancing the search for drug treatments.

   
Released: 19-Nov-2020 2:45 PM EST
The Lancet: Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response
Lancet

Older adults are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use against SARS-CoV-2 is effective in this group

12-Nov-2020 1:30 PM EST
New effective and safe antifungal isolated from sea squirt microbiome
University of Wisconsin–Madison

By combing the ocean for antimicrobials, scientists at the University of Wisconsin–Madison have discovered a new antifungal compound that efficiently targets multi-drug-resistant strains of deadly fungi without toxic side effects in mice.



close
2.65658